Amivas (US), LLC Announces U.S. Launch of Artesunate for Injection for Initial Treatment of Severe Malaria

Artesunate for Injection 110 mg, powder and solvent for solution is launching in the U.S. for initial treatment of severe malaria in adult and pediatric patients.

From 2007 until today, the product was available in the U.S. only through an expanded access investigational new drug (IND) program managed by the Centers for Disease Control and Prevention (CDC).

Amivas (US), LLC is now the sole manufacturer and wholesale distributor of Artesunate for Injection in U.S.

Company says its expertise is in helping patients and its “focus is on time.”